Clinical oncology research publications 2012

Department Of Oncology Faculty of Medicine, Dentistry and
Clinical Oncology Research Publications 2012
Clinical trials
Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J,
Paridaens R, Van de Velde CJH, Lonning PE, Morden J, Reise J, Cisar L, Menschik T, Coombes RC.
Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane
Study. J. Clinical Oncology: 30/7: 709-717, 2012.
Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla J-P, Sami A, Glaspy J, Juhos E, Wardley A,
Fornander T, Hainsworth J, Coleman RE, Modiano MR, Vinholes J, Pinter T, Rodriguez-Lescure A, Colwell
B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay M-A, Wilson
V, Rupin M, Houe V, Vogel C. for the TRIO/BCIRG 001 Investigators. Adjuvuant docetaxel, doxorubicin,
and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG
001 trial. The Lancet Oncology, published on line December 12 2012
Bone oncology
Brown JE, Coleman RE. Denosumab in patients with cancer – a surgical strike against the osteoclast.
Nature Reviews Clinical Oncology, 9/2, 110-8, 2012.
Smith MR, Saad F, Coleman RE, Shore N, Fizazi K, Tombal B, Miller K, Sieber P, Karsh L, Damiao R,
Tammela TL, Egerdie B, Van Poppel H, Chin J, Morote J, Gomez-Veiga F, Borkowski T, Ye Z., Kupic A,
Dansey R, Goessl C. Denosumab and bone-metastasis-free survival in men with castration-resistant
prostate cancer: results of a phase 3, randomised, placebo-controlled trial. The Lancet 379: 39-46, 2012.
Berruti A, Cook R, Saad F, Buttigliero C, Lipton A, Tampellini M, Lee K-A, Coleman RE, Smith
MR. Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing
zoledronic acid administration. The Oncologist 17: 645-652, 2012.
Coleman R., Gnant M., Morgan G., Clezardin P. Effects of bone-targeted agents on cancer progression and
mortality. Journal of National Cancer Institute 104: 1059-1067, 2012.
Brown JE, Cook R, Lipton A, Coleman RE. Serum Lactate Dehydrogenase Is Prognostic for Survival in
Patients With Bone Metastases From Breast Cancer: A Retrospective Analysis in Bisphosphonate-Treated
Patients. Clin Cancer Res Sep 4. [Epub ahead of print]. 2012.
Coleman RE, De Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, Sleeboom H,
Forbes J, Barrios C, Frassoldati A, Campbell I, Paija O, Martin N, Modi A, Bundred N. Zoledronic acid
(zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST
study): final 60-month results. Annals of Oncology Advance Access October 9, 2012.
Lester JE, Dodwell D, Brown JE, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, Horsman JM, Coleman
RE. Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the
ARIBON trial. J Bone Oncol 2012 1(2):57-62. 2012.
Vitovski S, Chantry AD, Lawson MA, Croucher PI. Targeting tumour-initiating cells with TRAIL based
combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo.
'PlosOne, May 2012 PMID:22615740.
Kingdon SJ, Coleman RE, Ellis L, Hancock BW. Deaths from gestational trophoblastic neoplasia: any
lessons to be learned? J Reprod Med. Jul-Aug; 57(7-8): 293-6, 2012.
Amir E, Clemons M, Purdie CA, Miller N, Quinlan P, Geddie W, Coleman RE, Freedman OC, Jordan LB,
Thompson AM. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of
multi-centre, multi-disciplinary prospective studies. Cancer Treatment Reviews 38(6):708-14, 2012.
Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll P, Hatton MQF, et.al
First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy
(TOPICAL): a double-blind, placebo-controlled, phase 3 trial. Lancet Oncology 2012;11:1161-70
Rowland C, Eiser C, Rowe R, Danson S. The effect of smoking on health related quality of life in lung
cancer patients: a systematic review. BMJ Supportive and Palliative Care 2:312-8, 2012.
Quinn A, Blackhall F, Wilson G, Danson S, Clamp A, Ashcroft L, Brierley J, Hasleton P. Extrapulmonary
small cell carcinoma: a clinicopathological study with identification of potential diagnostic mimics.
Histopathology 61(3):454-64, 2012.
Young RJ, Tin AW, Brown NJ, Jitlal M, Lee SM, Woll PJ. Analysis of circulating angiogenic biomarkers from
patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. Br J
Cancer 2012; 106:1153-1159.
Coté ML, Liu M, Bonassi S, Neri M, Schwartz AG, Christiani DC, et al. Increased risk of lung cancer in
individuals with a family history of the disease: A pooled analysis from the International Lung Cancer
Consortium. Eur J Cancer 2012; 48: 1957-1968.
Laboratory research
Ottewell PD, Brown HK, Jones M, Rogers TL, Cross SS, Brown NJ, Coleman RE, Holen I. Combination
therapy inhibits development and progression of mammary tumours in immunocompetent mice. Breast
Cancer Res Treat. 133: 523-536, 2012
Brown HK, Ottewell PD, Evans CA, Coleman RE, Holen I. A single administration of combination therapy
inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts. Journal of Bone
Oncology, 1, 47–56, 2012.
Thompson R, Woll P, Zhu Y, Meuth M, Danson S. Treatment with the Chk1 inhibitor Go6976 enhances
cisplatin cytotoxicity in SCLC cells. International Jourmal of Oncology 40(1):194-202, 2012.
Harrington K, Berrier A, Robinson M, Remenar E, Housset M, Hurtado de Mendoza F, Fayette J, Mehanna
H, El-Hariry I, Compton N, Franklin N, Biswas-Baldwin N, Lau M, Legenne P, Kumar R. Randomised Phase
II study of oranl lapatinib combined with cemoradiotherapy in patients with advanced squamous cell
carcinoma of the head and neck: Rationale for future randomized trials in human papilloma virus-negative
disease. Eur J Cancer: 49(7):1609-18,2013
Price A, Yellowlees A, Russell S, Faivre-Finn C, Gilligan D, Snee M, Hatton M, et al. Radical Radiotherapy
with or with out Gemcitabine in patients with early stage medically inoperable non small cell lung cancer.
Lung Cancer 2012;77:532-536
Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, Hancock BW, Harris SJ, Horwich A,
Hoskin PJ, Linch DC, Lister TA, Lucraft HH, Radford JA, Stevens AM, Syndikus I, Williams MV. Breast
cancer risk after supradiaphragmatic radiotherapy for Hodgkin's lymphoma in England and Wales: a National
Cohort Study. J Clin Oncol. 2012 Aug 1;30(22):2745-52
Late effects
Scott E, Daley AJ, Doll H, Woodroofe N, Coleman RE, Mutrie N, Crank H, Powers HJ, Saxton JM. Effects
of an exercise and hypocaloric healthy eating program on biomarkers associated with long-term prognosis
after early-stage breast cancer: a randomized controlled trial. Cancer Causes Control, published online 27
November 2012. DOI 10.1007/s10552-012-0104-x.
Thompson J, Coleman RE, Colwell B, Freeman J, Greenfield D, Holmes K, Mathers N, Reed M. Levels of
distress in breast cancer survivors approaching discharge from routine hospital follow-up. Psycho-Oncology.
2012 Published online DOI: 10.1002/pon.3229.

Source: http://www.sheffieldclinicalresearch.org/clientfiles/File/Clinical%20Oncology%20Research%20Publications%202012.pdf